Telitacicept a recombinant fusion protein targeting, neutralizing BLyS and APRIL, phase 3 study in RA MTX-IR at 24 wk, A

Telitacicept a recombinant fusion protein targeting, neutralizing BLyS and APRIL, phase 3 study in RA MTX-IR at 24 wk, ACR20 (60% vs 27% PBO), ACR50 (21% vs 6% PBO), reduced DAS28-ESR, no radiographic progression, Wang L Abst#L20 #ACR23 #ACRBest @RheumNow https://t.co/nuvizqQZsR https://t.co/PRtlea3AqU